Apyx Medical Corporation Reports Fourth Quarter and Full Year 2020 Financial Results; Introduces Full Year 2021 Financial Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Apyx Medical Corp. (APYX) Tops Q4 EPS by 7c, Revenues Beat; Offers FY21 Revenues Guidance Below Consensus
March 31, 2021 7:03 AM EDTApyx Medical Corp. (NASDAQ: APYX) reported Q4 EPS of ($0.04), $0.07 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $11.5 million versus the consensus estimate of $9.62 million.
Fourth Quarter 2020 Financial Summary:
Total revenue of $11.5 million, up 36.8% year-over-year.Advanced Energy revenue of $9.9 million, up 44.0% year-over-year.OEM revenue of $1.6 million, up 4.0% year-over-year.Net loss of $1.5 million, compared to net loss of $5.4 million for the fourth quarter of 2019.Adjusted EBITDA loss of $0.7 million, compared to adjusted EBITDA loss of $4.8 million for the fourth quarter of... More